Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis

被引：0
作者：
Maëlle Chappuis
Chloé Rousseau
Emma Bajeux
Sandrine Wiertlewski
David Laplaud
Emmanuelle Le Page
Laure Michel
Gilles Edan
Anne Kerbrat
机构：
[1] University Hospital,Department of Neurology
[2] University Hospital,Research Management Department
[3] University Hospital,Department of Epidemiology and Public Health
[4] University Hospital,Department of Neurology
[5] University Hospital,CIC
来源：
Journal of Neurology | 2023年 / 270卷
关键词：
Multiple sclerosis; Treatment discontinuation; Age;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：413 / 422
页数：9
相关论文
共 50 条
  • [31] First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence
    Ferraro, Diana
    Camera, Valentina
    Baldi, Eleonora
    Vacchiano, Veria
    Curti, Erica
    Guareschi, Angelica
    Malagu, Susanna
    Montepietra, Sara
    Strumia, Silvia
    Santangelo, Mario
    Caniatti, Luisa
    Foschi, Matteo
    Lugaresi, Alessandra
    Granella, Franco
    Pesci, Ilaria
    Motti, Luisa
    Neri, Walter
    Immovilli, Paolo
    Montanari, Enrico
    Vitetta, Francesca
    Simone, Anna Maria
    Sola, Patrizia
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (10) : 1803 - 1807
  • [32] An epidemiological study on the course of disease and therapeutic considerations in relapsing-remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM)
    Schmidt, Stephan
    Koehler, Juergen
    Winterstein, Christine
    Schicklmaier, Petra
    Kallmann, Boris
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
  • [33] Infections in patients with multiple sclerosis: Implications for disease-modifying therapy
    Celius, E. G.
    ACTA NEUROLOGICA SCANDINAVICA, 2017, 136 : 34 - 36
  • [34] Vaccinations in multiple sclerosis patients receiving disease-modifying drugs
    Otero-Romero, Susana
    Ascherio, Alberto
    Lebrun-Frenay, Christine
    CURRENT OPINION IN NEUROLOGY, 2021, 34 (03) : 322 - 328
  • [35] Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register
    D'Amico, Emanuele
    Zanghi, Aurora
    Romeo, Marzia
    Cocco, Eleonora
    Maniscalco, Giorgia Teresa
    Brescia Morra, Vincenzo
    Paolicelli, Damiano
    De Luca, Giovanna
    Galgani, Simonetta
    Amato, Maria Pia
    Salemi, Giuseppe
    Inglese, Matilde
    Confalonieri, Paolo Agostino
    Lus, Giacomo
    Avolio, Carlo
    Gallo, Antonio
    Vianello, Marika
    Onofrj, Marco
    Filippi, Massimo
    Trojano, Maria
    Patti, Francesco
    NEUROTHERAPEUTICS, 2021, 18 (02) : 905 - 919
  • [36] Association of Obesity With Multiple Sclerosis Risk and Response to First-line Disease Modifying Drugs in Children
    Huppke, Brenda
    Ellenberger, David
    Hummel, Hannah
    Stark, Wiebke
    Roebl, Markus
    Gaertner, Jutta
    Huppke, Peter
    JAMA NEUROLOGY, 2019, 76 (10) : 1157 - 1165
  • [37] Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes
    Yano, Hajime
    Gonzalez, Cindy
    Healy, Brian C.
    Glanz, Bonnie, I
    Weiner, Howard L.
    Chitnis, Tanuja
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 35 : 119 - 127
  • [38] Clinical and epidemiological characteristics of multiple sclerosis patients receiving disease-modifying treatment in Poland
    Kapica-Topczewska, Katarzyna
    Collin, Francois
    Tarasiuk, Joanna
    Chorazy, Monika
    Czarnowska, Agata
    Kwasniewski, Miroslaw
    Brola, Waldemar
    Bartosik-Psujek, Halina
    Adamczyk-Sowa, Monika
    Kochanowicz, Jan
    Kulakowska, Alina
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2020, 54 (02) : 161 - 168
  • [39] Stoppers and non-starters of disease-modifying treatment in multiple sclerosis
    Grytten, N.
    Aarseth, J. H.
    Espeset, K.
    Johnsen, G. B.
    Wehus, R.
    Lund, C.
    Haugstad, R. C.
    ACTA NEUROLOGICA SCANDINAVICA, 2013, 127 (02): : 133 - 140
  • [40] Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment
    Visser, Leo H.
    Heerings, Marco A.
    Jongen, Peter J.
    van der Hiele, Karin
    PATIENT PREFERENCE AND ADHERENCE, 2016, 10 : 659 - 667
12345